April 19, 2018 01:21 PM EDT
Pharma

GW Phar­ma walks away from ad­comm with unan­i­mous sup­port for an­ti-seizure med. An OK shouldn’t take long now

John Carroll

Editor & Founder

Any small doubts about GW Phar­ma’s $GW­PH chances for a quick OK for their land­mark, cannabis-based drug Epid­i­olex were quick­ly laid to rest to­day with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

A service from the Financial Times